

Children's Mercy Kansas City

SHARE @ Children's Mercy

Manuscripts, Articles, Book Chapters and Other Papers

11-29-2016

Monitoring change in volume of calcifications in juvenile idiopathic inflammatory myopathy: a pilot study using low dose computed tomography.

Maria Ibarra

Children's Mercy Hospital

Cynthia Rigsby

Gabrielle A. Morgan

Christina L. Sammet

Chiang-Ching Huang

See next page for additional authors

Follow this and additional works at: <https://scholarlyexchange.childrensmercy.org/papers>



Part of the [Investigative Techniques Commons](#), [Pediatrics Commons](#), and the [Rheumatology Commons](#)

Recommended Citation

Ibarra, M., Rigsby, C., Morgan, G. A., Sammet, C. L., Huang, C., Xu, D., Targoff, I. N., Pachman, L. M. Monitoring change in volume of calcifications in juvenile idiopathic inflammatory myopathy: a pilot study using low dose computed tomography. *Pediatr Rheumatol Online J* 14, 64-64 (2016).

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact library@cmh.edu.

Creator(s)

Maria Ibarra, Cynthia Rigsby, Gabrielle A. Morgan, Christina L. Sammet, Chiang-Ching Huang, Dong Xu, Ira N. Targoff, and Lauren M. Pachman

RESEARCH ARTICLE

Open Access



Monitoring change in volume of calcifications in juvenile idiopathic inflammatory myopathy: a pilot study using low dose computed tomography

Maria Ibarra¹, Cynthia Rigsby^{2,3}, Gabrielle A. Morgan⁴, Christina L. Sammet^{2,3}, Chiang-Ching Huang⁵, Dong Xu⁴, Ira N. Targoff⁶ and Lauren M. Pachman^{4*}

Abstract

Background: Dystrophic calcifications may occur in patients with Juvenile Idiopathic Inflammatory Myopathy (JIIM) as well as other connective tissue and metabolic diseases, but a reliable method of measuring the volume of these calcifications has not been established. The purpose of this study is to determine the feasibility of low dose, limited slice, Computed Tomography (CT) to measure objectively in-situ calcification volumes in patients with JIIM over time.

Methods: Ten JIIM patients (eight JDM, two Overlap) with calcifications were prospectively recruited over a 2-year period to undergo two limited, low dose, four-slice CT scans. Calculation of the volume of calcifications used a CT post processing workstation. Additional patient data included: Disease Activity Scores (DAS), Childhood Myositis Assessment Scale (CMAS), myositis specific antibodies (MSA), and the TNF α -308 promoter region A/G polymorphism. Statistical analysis utilized the Pearson correlation coefficient, the paired *t*-test and descriptive statistics.

Results: Ten JIIM, mean age 14.54 ± 4.54 years, had a duration of untreated disease of 8.68 ± 5.65 months. MSA status: U1RNP (1), PM-Scl (1), Ro (1, 4 indeterminate), p155/140 (2), MJ (3), Mi-2 indeterminate (1), negative (3). 4/8 JDM (50%) were TNF- α -308 A+. Overall, the calcification volumes tended to decrease from the first to the second CT study by 0.5 cm^3 (from $2.79 \pm 1.98 \text{ cm}^3$ to $2.29 \pm 2.25 \text{ cm}^3$). The average effective radiation dose was 0.007 ± 0.002 , 0.010 ± 0.005 , and 0.245 mSv for the upper extremity, lower extremity and chest, respectively (compared to a standard chest x-ray– 0.02 mSv effective dosage).

Conclusion: We conclude: 1) the limited low dose CT technique provides objective data about volume of the calcifications in JIIM; 2) measuring the volume of calcifications in an extremity is associated with minimal radiation exposure; 3) This method may be useful to evaluate the efficacy of therapies for JIIM dystrophic calcification.

Keywords: Computed Tomography (CT), Calcification volume, Juvenile idiopathic inflammatory myopathy, Overlap syndrome, Calcification

* Correspondence: pachman@northwestern.edu

⁴Cure JM Center of Excellence, Stanley Manne Research Institute affiliated with Ann & Robert H. Lurie Children's Hospital of Chicago, 225 East Chicago Avenue, Box 212, Chicago, IL 60611, USA

Full list of author information is available at the end of the article

Background

In children with JIIM, such as Juvenile Dermatomyositis (JDM) and Overlap Syndrome, dystrophic calcifications are a common and debilitating complication. The reported calcifications in JDM range from 71% [1] to 8% [2] with 40% most frequently cited [3]. These calcifications usually occur in children with chronic inflammation and hypoxia associated with JIIM, which includes JDM, Polymyositis and Overlap Syndromes as well as in patients with other rheumatic diseases such as Scleroderma [4] and Systemic Lupus Erythematosus [5, 6].

Plain radiography is effective for the detection of calcinosis and the categorization of morphological patterns of calcification [7]. Although radiography is recommended for the initial imaging of calcinosis, it fails to evaluate objectively the volume of calcifications. Case reports have employed different types of whole body scans (scintigraphy using Technetium methylene diphosphonate (Tc-99 m MDP) and Tc-99 m pyrophosphate and Strontium nitrate) in an attempt to identify the location of the calcifications and to provide a quantifiable assessment of their extent, as well as to develop a method to monitor the child's therapeutic response [8]. Scintigraphic evaluation using Tc-99 m MDP can effectively delineate sites of dystrophic calcifications in JDM and it is more sensitive in detecting visceral calcifications than plain radiographs [9]. However, scintigraphy has failed to provide a quantitative estimation of the volume of the calcification. In contrast, micro CT and synchrotron x-ray diffraction studies of calcified deposit samples from four children with the diagnosis of JDM characterized the microstructure of calcinosis, and demonstrated excellent sensitivity with respect to quantitation of amount and spatial distribution of minerals in these calcifications samples [10]. These studies suggested that CT could be used to measure the calcifications occurring in the soft tissues of children with JIIM, as this method had been effective in the experimental mouse model [11].

The purpose of this pilot study was to determine the feasibility of the use of low dose, limited slice CT as an objective measure of in-situ calcification volume, over time, in patients with JIIM.

Methods

Patient population

Approval was obtained from the Ann & Robert H. Lurie Children's Hospital of Chicago Institutional Review Board to perform this prospective study (IRB#2008-13316). Inclusion criteria for study enrollment consisted of a diagnosis of JIIM and documentation of moderate to severe calcifications as determined by the assessor on clinical evaluation. One hundred and fifty JIIM patients were followed in our clinic during the time of the study. Of those, 14 (9.3%) had moderate to severe calcification;

ten of these children were available for study; they gave their consent and were enrolled in the study. Eight of these children had severe calcifications and fulfilled the Peter and Bohan [12] criteria for definite/possible JDM and two of the patients had Overlap Syndrome and moderate calcifications. The duration of untreated disease was given by the patient's family. Each of the ten cases had two scans over a 2 year period. For consistency purposes, a single individual, the principal investigator (PI), marked the specific accessible area of the calcification to be scanned. The PI performed a complete physical examination; anatomic landmarks of the area were noted as a reference point for future scans.

Laboratory assessment

TNF- α -308 promoter polymorphism

The A/G polymorphism in the -308 promoter region was determined by PCR, following established methodology [13].

Myositis Specific Antibody (MSA)

Each patient's sera was analyzed at diagnosis and periodically thereafter, as new antibodies were recognized, by the Oklahoma Medical Research Foundation Clinical Immunology Laboratory, following methods previously outlined [14, 15].

Clinical assessment

Disease Activity Scores (DAS)

The patient's status with respect to 1) total DAS score; 2) skin involvement (DAS-S) as well as, 3) muscle strength and endurance (DAS-M) was assessed at the time of every visit according to a standard protocol [16].

The Childhood Myositis Assessment Score (CMAS)

An estimate of performance was obtained at every visit by a physical therapist, who was an independent observer [17].

Imaging of calcifications

A limited four-slice CT was performed on a Siemens Somatom Sensation 64 CT scanner in the area of greatest calcium burden and utilized 100kVp, 100 mAs, 3 mm reconstructed slice thickness. Only the limb of interest was included in the scan field of view. For example, examination of the arm was performed in an image "arms-over-head" stance instead of alongside of the body to limit radiation exposure of the torso. The area of soft tissue calcifications was determined by thresholding the calcifications from the range of Hounsfield units of the calcifications (114–3017 Hounsfield units) using software on a Siemens CT workstation (MMWP, Siemens Medical Solutions, Malvern, PA). No sedation was required. There was a mean interval of 7.18 ± 2.33 months between the first scan and second scans. The computed tomography dose index

(CTDI) and the dose length product (DLP) were reported by the scanner. The DLP was used to estimate the patient effective dose using published methods [18, 19] for the chest and lower extremities. Due to a paucity of data on the subject, estimates of the upper extremity effective dose were performed by a physicist based on published conversion factors for lower extremities [18, 19].

Statistical analysis

Presentation of demographic and baseline characteristics used descriptive statistics. A paired t-test analyzed volume changes of calcifications in JIIM patients over time. Pearson correlation coefficient was used to determine the correlation between change in calcification volume and duration of active disease.

Results

Demographics and disease state

The demographics of the ten patients enrolled in this proof of principle study are presented in Table 1. The patients had active inflammatory disease for a mean of 8.68 ± 5.65 months. At the time of both scans, the patients still displayed symptoms of moderately active JIIM. Their DAS-S and DAS-M at the first scan were 6 ± 2.3 and 3 ± 3.7 respectively; (maximal DAS-M = 11, maximal DAS-S = 9; normal = 0 for both DAS-S and DAS-M) with a CMAS of 43 ± 7.4 (normal CMAS = 52). At the time of the second scan, their disease activity demonstrated very little improvement (DAS-S = 5 ± 2.2 , DAS-M = 3 ± 2.7 , CMAS = 44 ± 9.5). Two of the ten patients had Overlap Syndrome, one each positive for either Pm/SCL or U1RNP indeterminate. The remainder of the group was classified as JDM (4 Ro indeterminate; 1 Mi-2 indeterminate; three MJ positive; two p155/140 positive, one Ro positive; three negative for MSA). Of the ten subjects, eight had JDM and 4/8 (50%) were positive for TNF- α -308 GA polymorphism, the rest were GG,

which was consistent with our previous findings [20]. Before entering the study, the patients had been given a variety of medications including; methotrexate ($n = 7$), hydroxychloroquine ($n = 6$), cyclosporine ($n = 4$), mycophenolate mofetil (MMF) ($n = 4$), prednisone ($n = 6$), intravenous methylprednisolone ($n = 2$) and intravenous gamma globulin (IVIg) ($n = 2$). During the study, the following medications were added: prednisone ($n = 2$), intravenous methylprednisolone ($n = 3$) and MMF ($n = 3$). All the children with calcifications were placed on at least two medications, but only five had been given a high dose intermittent pulse methylprednisolone. By end of the study, a total of six children had been given MMF, which did improve their rash [21]. Of note, the four patients for whom cyclosporine was proscribed stated that they were non-compliant with respect to the cyclosporine and had low serum levels of the drug.

Calcifications and CT scanning data

The calcifications were located as follows: three above the elbow, two in the forearm, one at the elbow, one in the area of the tibia, two around the knee and one in the chest wall. The average CTDI and DLP for the upper extremity ($n = 12$), lower extremity ($n = 6$) and chest ($n = 1$) are presented in Table 2.

Table 2. The CTDI and DLP are relatively similar for upper and lower extremities scanned in this study but the chest has a higher effective dose than the extremity studies. It is important to note, for comparison, that the comparable average effective radiation dose for a 15 year old child's standard chest x-ray is 0.02 mSv [22], compared to the average effective doses above for the extremities of 0.007 and 0.010mSV), where the majority of the calcifications occur. Figure 1a presents an axial CT image of the upper arm showing a large cluster of calcifications medially, while Fig. 1b depicts the same axial CT image showing the calculated calcification volume highlighted in gray.

Table 1 Clinical features of patients with juvenile idiopathic inflammatory myopathy

	Gender	Diagnosis	Duration of untreated disease (DUD) (mo)	Location of calcification	MSA status	TNF- α -308	Age at scan 1 (years)	Age at scan 2 (years)
Case 1	F	JDM	2.00	Arm	Ro indeterminate, MJ+	GG	11.25	11.71
Case 2	M	JDM	2.99	Forearm	Ro indeterminate, MJ+	GG	13.94	14.43
Case 3	F	JDM	2.00	Forearm	Ro indeterminate, p155/140+	GA	10.93	11.43
Case 4	M	JDM	0.36	Tibia	Mi-2 indeterminate	GA	16.32	16.86
Case 5	F	JDM	14.32	Knee	Negative	GG	8.89	9.48
Case 6	F	JDM	16.99	Arm	Negative	GG	20.58	21.17
Case 7	F	OVERLAP	0.00	Elbow	PMScl+	GG	13.72	14.35
Case 8	F	JDM	11.99	Knee	Negative	GA	20.06	20.73
Case 9	F	OVERLAP	10.05	Chest	U1RNP indeterminate, Ro indeterminate, MJ+	GG	20.27	20.93
Case 10	F	JDM	20.04	Arm	Ro+, p155/140+	GA	9.46	9.88

Table 2 Average radiation dose estimates by CT scan location

	Total number of scans	Average CTDI mGy (stdv)	Average DLP mGy ^a cm (stdv)	Average effective dose mSv (stdv)
Upper extremity	12	4.322 (1.656)	16.133 (4.770)	0.007 (0.002)
Lower extremity	6	4.283 (0.581)	18.167 (3.488)	0.010 (0.005)
Chest ^a	1	4.200	17.000	0.245

^amissing radiation information from first scan

The volume of the calcifications

There was a positive association of the change of the volume of calcification and DUD although this association was not statically significant (correlation 0.27, $p = 0.46$ Pearson correlation coefficient), (Fig. 2). The average size of calcifications at the first scan was 2.79 ± 1.98 and 2.29 ± 2.25 cm³ at the second scan, for an average decrease in size of 0.51 ± 1.38 cm³ (approximately 18%). However, the 6/10 who were compliant with their medications, did have a decrease in calcification volume from 2.32 ± 1.77 cm³ on the first scan to 1.00 ± 0.92 cm³ on the second scan, which was a measurable average decrease of 1.32 ± 1.14 cm³ (Fig. 3).

Discussion

The present study represents the first pilot study to evaluate objectively the volume of calcifications in patients with JIIM over time. The mechanisms controlling the pathophysiology of calcifications remain poorly understood. Studies of the composition of these calcifications have shown that hydroxyapatite is the main mineral component, as well as calcium carbonate [23, 24]. Other bone matrix proteins such as osteonectin, osteopontin and bone sialoprotein have been documented [24], in addition to members of the integrin family [25]. Reported risk factors for the development of calcinosis include delayed diagnosis and treatment along with inadequate levels and duration of immunosuppressive therapy, [26] suggesting that prolonged inflammation contributes to tissue injury which promotes the calcium deposition. A common feature among all the children in this study was the persistent and chronic course of an active inflammatory process, which

may be a major factor in the development/progression of calcifications in children with myositis [20]. Thirty percent of the JIIM group had a substitution of A at the TNF α -308 promoter region, which is similar to the 27–30% frequency in the general population, while 50% of the patients with JDM (4/8) were positive for the A substitution [20].

This study was not designed to test the efficacy of specific agents to elicit change in the volume of the calcifications, but to document that the single slice CT gives sufficient information to evaluate and compare outcomes. Our analysis of 20 CT scans of patients with JIIM and calcifications during a 2 year period while they were given immunosuppressive therapy showed a tendency for the specific calcification to decrease in volume in that time frame. In this group, 6/10 had positive MSAs, of whom 3/8 JDM were positive for one of the more frequently occurring MSAs, anti-MJ, reported to be associated with calcification [27].

We are not aware of any previous study that has used an objective method to measure the volume of calcifications embedded in the soft tissue of children with JIIM. For patients with systemic sclerosis, multidetector computed tomography with multiplanar format has been employed successfully [28]. Experimentally, microcomputed tomography was employed to measure the volume of calcification in Abcc6 deficient mice [29] and to monitor the rate of resolution of induced calcification in mice with defective macrophage function [11].

Effective radiation dose in CT is dependent on three primary factors: the amount of radiation necessary to achieve the desired contrast between tissues, the extent




Fig. 1 a Axial CT image of the upper arm of a child with JDM, showing a large cluster of calcifications medially. **b** The same axial CT image showing the calculated calcification volume highlighted in gray

We speculate that this method may be a useful research tool to monitor progression and regression of calcifications. The four slice CT method offers the possibility of detecting and documenting change in the volume of calcifications in children over time, and may be a useful adjunct in assessing the child's response to therapy.

Abbreviations

CMAS: Childhood myositis assessment scale; CT: Computed tomography; CTDI: Computed tomography dose index; DAS: Disease activity score; DLP: Dose length product; JDM: Juvenile dermatomyositis; JJIM: Juvenile idiopathic inflammatory myopathy; MSA: Myositis specific antibodies

Acknowledgements

This study could not have been performed without the support of the CureJM Foundation, for which the authors are very thankful. Expert administrative assistance was supplied by Ms Brittiany Hudanick, and was much appreciated. Finally, the authors valued the reviewer's expert comments, which served to improve the manuscript.

Funding

Support for this study was provided by the Cure JM Foundation.

Availability of data and materials

All the available data, pertinent to this topic has been presented in this manuscript.

Authors' contributions

The PI and first author, MI designed and executed this study as her Pediatric Rheumatology Fellowship project. She collected the data, wrote and edited the many drafts of the manuscripts and gave her approval of the final draft of this manuscript for publication. CR the second author, arranged for the CT studies, reviewed the data with MI, selected the figures used in this manuscript and reviewed and approved the final draft of this manuscript for publication. GAM data base manager, entered the data, participated in the creation of the figures, reviewed the many versions of the manuscript and gave her final approval of this submitted version. CLS is the radiation safety officer for the Ann and Robert H. Lurie Children's Hospital of Chicago. She reviewed the data, verified the dosage calculations and concurred with the conclusions reached by this study. She reviewed the final manuscript and gave her approval for publication. CCH Biostatistics, participated in the study design, reviewed the data, and performed the analysis of the data. He reviewed the final manuscript and gave it his approval to be published. DX participated in the study design, performed the assays for the TNF- α -308 promotor polymorphism, and reviewed the final manuscript, giving his consent to publish. IT performed the immunological assays for the Myositis Specific Antibodies in the sera of the patients included in this study. He reviewed the final manuscript and gave his approval for publication. LMP mentored MI in the design of the study, data collection and analysis and in the preparation of the manuscript. She reviewed the final manuscript and gave her approval for publication.

Authors' information

M. Ibarra, MD, Associate Professor, Division of Rheumatology, Children's Mercy Hospital, Kansas City, Missouri, USA.
C. K. Rigsby, MD, Department of Medical Imaging, Ann & Robert H. Lurie Children's Hospital of Chicago, Professor of Radiology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
G.A. Morgan, MA, Database Manager, Stanley Manne Children's Research Institute, Cure JM Center of Excellence in Juvenile Myositis (JM) Research and Care, Ann & Robert H. Lurie Children's Hospital of Chicago, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
C.L. Sammet, Ph.D., Research Assistant Professor, Department of Radiology, Northwestern University, Medical Physicist, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
I.N. Targoff, MD, Professor, Department of Internal Medicine, The University of Oklahoma College of Medicine, Oklahoma City, Oklahoma; Veterans Affairs Medical Center (INT), University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.

C.C. Huang, PhD, Associate Professor, Joseph J. Zilber School of Public Health, University of Wisconsin, Milwaukee, Wisconsin, USA.
D. Xu, MD, Research Assistant Professor, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Stanley Manne Children's Research Institute, Cure JM Center of Excellence in Juvenile Myositis (JM) Research and Care.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

All the authors have reviewed the final manuscript and given their consent for publication.

Ethics approval and consent to participate

This study was reviewed by the Lurie Children's IRB board and was approved, (IRB#2008-13316).

Departments and Institutions to which work is attributed

Ann & Robert H. Lurie Children's Hospital of Chicago, Departments of Radiology and Rheumatology.

Sources of support

Supported by the Cure JM Foundation.

Author details

¹Division of Pediatric Rheumatology, Children's Mercy Hospital, 2401 Gillham Road, Kansas City, Missouri 64108-4619, USA. ²Department of Medical Imaging, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA. ³Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. ⁴Cure JM Center of Excellence, Stanley Manne Research Institute affiliated with Ann & Robert H. Lurie Children's Hospital of Chicago, 225 East Chicago Avenue, Box 212, Chicago, IL 60611, USA. ⁵Joseph J. Zilber School of Public Health, University of Wisconsin, Milwaukee, WI, USA. ⁶The Department of Internal Medicine, The University of Oklahoma, Norman, OK, USA.

Received: 10 August 2016 Accepted: 16 November 2016

Published online: 29 November 2016

References

1. Faller G, Mistry BJ, Tikly M. Juvenile dermatomyositis in South African children is characterised by frequent dystrophic calcification: a cross sectional study. *Pediatr Rheumatol Online J*. 2014;12:2.
2. Pachman LM, Morgan GA, Curran ML, et al. Decreased frequency of dystrophic calcifications in children with juvenile dermatomyositis: a 10-year study [abstract]. *Arthritis Rheum*. 2012;64 Suppl 10:301.
3. Hoeltzel MF, Oberle EJ, Robinson AB, et al. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. *Curr Rheumatol Rep*. 2014;16(12):467.
4. Shahi V, Wetter DA, Howe BM, et al. Plain radiography is effective for the detection of calcinosis cutis occurring in association with autoimmune connective tissue disease. *Br J Dermatol*. 2014;170(5):1073–9.
5. Nazir L, Saeed M. The calcium invasion: calciphylaxis in Lupus. *J Pak Med Assoc*. 2015;65(4):427–8.
6. Tristano AG, Villarreal JL, Rodriguez MA, et al. Calcinosis cutis universalis in a patient with systemic lupus erythematosus. *Clin Rheumatol*. 2006;25(11):70–4 [Published Online First: 18 May 2005].
7. Blane CE, White SJ, Braunstein EM, et al. Patterns of calcification in childhood dermatomyositis. *AJR Am J Roentgenol*. 1984;142(2):397–400.
8. Bar-Sever Z, Mukamel M, Harel L, et al. Scintigraphic evaluation of calcinosis in juvenile dermatomyositis with Tc-99 m MDP. *Clin Nucl Med*. 2000;25(12):1013–6.
9. Sarmiento AH, Alba J, Lanaro AE, et al. Evaluation of soft-tissue calcifications in dermatomyositis with 99mTc-phosphate compounds: case report. *J Nucl Med*. 1975;16(6):467–8.
10. Stock S, Ignatiev K, Lee P, et al. Pathological calcification in juvenile dermatomyositis (JDM): microCT and synchrotron x-ray diffraction reveal hydroxyapatite with varied microstructures. *Connect Tissue Res*. 2004;45(4–5):248–56.

11. Zhao Y, Urganus AL, Spevak L, et al. Characterization of dystrophic calcification induced in mice by cardiotoxin. *Calcif Tissue Int.* 2009;85(3):267–75. doi:10.1007/s00223-009-9271-5 [published Online First: 20 Aug 2009].
12. Bohan A, Peter JB. Polymyositis and Dermatomyositis (first of two parts). *N Engl J Med.* 1975;292(7):344–7.
13. Toonen EJ, Barrera P, Fransen J, et al. Meta-analysis identified the TNFA-308G > A promoter polymorphism as a risk factor for disease severity in patients with rheumatoid arthritis. *Arthritis Res Ther.* 2012;14(6):R264.
14. Trieu EP, Targoff IN. Immunoprecipitation: Western blot for proteins of low abundance. *Methods Mol Biol.* 2015;1312:327–42.
15. Rider LG, Shah M, Mamyrova G, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. *Medicine (Baltimore).* 2013;92(4):223–43.
16. Bode RK, Klein-Gitelman MS, Miller ML, et al. Disease activity scores for children with juvenile dermatomyositis: reliability and validity evidence. *Arthritis Rheum.* 2003;49(1):7–15.
17. Huber AM, Feldman BM, Rennebohm RM, et al. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. *Arthritis Rheum.* 2004;50(5):1595–603.
18. Saltybaeva N, Jafari ME, Hupfer M, et al. Estimates of effective dose for CT scans of the lower extremities. *Radiology.* 2014;273(1):153–9. doi:10.1148/radiol.14132903 [published Online First: 10 June 2014].
19. Deak PD, Smal Y, Kalender WA. Multisection CT protocols: sex- and age-specific conversion factors used to determine effective dose from dose-length product. *Radiology.* 2010;257(1):158–66.
20. Pachman LM, Liotta-Davis MR, Hong DK, et al. TNF-alpha-308A allele in Juvenile Dermatomyositis: association with increased production of TNF-alpha, disease duration and pathological calcifications. *Arthritis Rheum.* 2000;43(10):2368–77.
21. Rouster-Stevens KA, Morgan GA, Wang D, et al. Mycophenolate mofetil: a possible therapeutic agent for children with Juvenile Dermatomyositis. *Arthritis Care Res (Hoboken).* 2010;62(10):1446–51.
22. Biswas D, Bible JE, Bohan M, et al. Radiation exposure from musculoskeletal computerized tomographic scans. *J Bone Joint Surg Am.* 2009;91(8):1882–9.
23. Eidelman N, Boyde A, BushbyAJ, et al. Microstructure and mineral composition of dystrophic calcifications associated with the idiopathic inflammatory myopathies. *Arthritis Res Ther.* 2009;11(5):R159. doi:10.1186/ar2841 [published Online First: 25 Oct 2009].
24. Pachman LM, Veis A, Stock S, et al. Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation. *Arthritis Rheum.* 2006;54(10):3345–50.
25. Urganus AL, Zhao YD, Pachman LM. Juvenile dermatomyositis calcifications selectively displayed markers of bone formation. *Arthritis Rheum.* 2009;61(4):501–8.
26. PachmanLM, Abbott K, Sinacore JM, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. *J Pediatr.* 2006;148(2):247–53.
27. Tansley SL, Betteridge ZE, Shaddick G, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. *Rheumatology (Oxford).* 2014;53(12):2204–8. doi:10.1093/rheumatology/keu259 [published Online First: 1 Jul 2014].
28. Freire V, Becce F, Feydy A, et al. MDCT imaging of calcinosis in systemic sclerosis. *Clin Radiol.* 2013;68(3):302–9. doi:10.1016/j.crad.2012.07.009 [published Online First: 5 Sep 2012].
29. Le Corre Y, Le Saux O, Froeliger F, et al. Quantification of the calcification phenotype of Abcc6-deficient mice with microcomputed tomography. *Am J Pathol.* 2012;180(6):2208–13. doi:10.1016/j.ajpath.2012.02.007 [published Online First: 31 Mar 2012].
30. Ahmed BA, Connolly BL, Shroff P, et al. Cumulative effective doses from radiologic procedures for pediatric oncology patients. *Pediatrics.* 2010;126(4):e851–8. doi:10.1542/peds.2009-2675 [published Online First: 27 Sep 2010].
31. Hu S, Hoffman EA, Reinhardt JM. Automatic Lung Segmentation for accurate quantitation of volumetric x-ray CT images. *IEEE Trans Med Imaging.* 2001;20(6):490–8.
32. Lin EC. Radiation risk from medical imaging. *Mayo Clin Proc.* 2010;85(12):1142–6.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

